Escalating anti-tumour necrosis factor exposure with reductions in surgical resection rates in paediatric inflammatory bowel disease: an 18-year real-world population-based cohort study
Escalating anti-tumour necrosis factor exposure with reductions in surgical resection rates in paediatric inflammatory bowel disease: an 18-year real-world population-based cohort study
OBJECTIVE: To evaluate the relationship between anti-tumour necrosis factor (TNF) use and surgical resection rates in a regional paediatric inflammatory bowel disease (IBD) cohort.
METHODS: This retrospective cohort study used prospectively maintained electronic data from a regional UK paediatric gastroenterology centre (2007-2024). Included were individuals with modified Porto IBD diagnosis, aged ≤17 years. Annual prevalent IBD population was estimated using incident diagnoses and transition to adult services. Abdominal surgery rates (strictureplasty, resection, primary stoma) and anti-TNF administration were collected and prevalence calculated. Three anti-TNF epochs, defined by the European Crohn's and Colitis Organisation/European Society of Paediatric Gastroenterology, Hepatology and Nutrition guidelines in 2014 and 2020, were compared: Epoch-1 (2007-2013; <20% anti-TNF), Epoch-2 (2014-2020; 20%-50%) and Epoch-3 (2021-2024; >50%). Kaplan-Meier analysis with log-rank testing compared surgery-free survival between early and later anti-TNF treatment groups.
RESULTS: One thousand five hundred and thirty-eight children were included (915 Crohn's disease (CD), 529 ulcerative colitis (UC) and 94 IBD-unclassified). Median age at diagnosis was 13.3 years, and the prevalent population increased (253-597 patients). Anti-TNF-treated prevalence rose across epochs (5.9%, 31.9%, 61.1%; p<0.001). Resection rates declined 3.93%, 1.57% and 1.09% (Epoch 1-3) (p=0.003). Rates did not significantly decrease from Epoch 2 to 3 (p=0.217). CD surgery significantly decreased (4.9%, 1.7%, 1.5%, p=0.006); trends in UC rates did not reach significance (1.89%, 1.55%, 0.56%, p=0.314). Time to anti-TNF from diagnosis decreased (1.2, 0.8 and 0.26 years, p=0.008). Early vs later anti-TNF initiation was not associated with surgery-free survival.
CONCLUSION: We report a significant increase in anti-TNF prevalence, with earlier deployment. Surgical resection rates have declined and plateaued; reflecting reduced CD surgery. Future research should focus on optimised anti-TNF and second-line biologic deployment to move beyond current levels of surgery.
Green, Zachary
b3269022-c0a6-42db-859d-d92c4cc5f4f0
Nicholas, Myrna
c5a1af5b-3b38-49b8-a46b-d323fae0df98
Vuijk, Stephanie
8a84ca7f-6643-4c6e-a1dc-1faebc7da0c4
Stanton, Mike
2eeae5fc-23c6-4d7d-80c6-f74efaf677f4
Bakewell, Christopher
0e949bd2-97a5-411a-8e5e-aee8320953ec
Coelho, Tracy
a78b627c-ea78-41e1-9553-0390921e3c93
Batra, Akshay
822f891e-87ca-41d9-b68d-27c395e88809
Afzal, Nadeem
5148f35e-6788-4dbd-a50f-c303a4948d60
Ennis, Sarah
7b57f188-9d91-4beb-b217-09856146f1e9
Beattie, Robert M
9a66af0b-f81c-485c-b01d-519403f0038a
Ashton, James
03369017-99b5-40ae-9a43-14c98516f37d
Green, Zachary
b3269022-c0a6-42db-859d-d92c4cc5f4f0
Nicholas, Myrna
c5a1af5b-3b38-49b8-a46b-d323fae0df98
Vuijk, Stephanie
8a84ca7f-6643-4c6e-a1dc-1faebc7da0c4
Stanton, Mike
2eeae5fc-23c6-4d7d-80c6-f74efaf677f4
Bakewell, Christopher
0e949bd2-97a5-411a-8e5e-aee8320953ec
Coelho, Tracy
a78b627c-ea78-41e1-9553-0390921e3c93
Batra, Akshay
822f891e-87ca-41d9-b68d-27c395e88809
Afzal, Nadeem
5148f35e-6788-4dbd-a50f-c303a4948d60
Ennis, Sarah
7b57f188-9d91-4beb-b217-09856146f1e9
Beattie, Robert M
9a66af0b-f81c-485c-b01d-519403f0038a
Ashton, James
03369017-99b5-40ae-9a43-14c98516f37d
Green, Zachary, Nicholas, Myrna, Vuijk, Stephanie, Stanton, Mike, Bakewell, Christopher, Coelho, Tracy, Batra, Akshay, Afzal, Nadeem, Ennis, Sarah, Beattie, Robert M and Ashton, James
(2026)
Escalating anti-tumour necrosis factor exposure with reductions in surgical resection rates in paediatric inflammatory bowel disease: an 18-year real-world population-based cohort study.
BMJ Open Gastroenterology, 13 (1), [e002344].
(doi:10.1136/bmjgast-2026-002344).
Abstract
OBJECTIVE: To evaluate the relationship between anti-tumour necrosis factor (TNF) use and surgical resection rates in a regional paediatric inflammatory bowel disease (IBD) cohort.
METHODS: This retrospective cohort study used prospectively maintained electronic data from a regional UK paediatric gastroenterology centre (2007-2024). Included were individuals with modified Porto IBD diagnosis, aged ≤17 years. Annual prevalent IBD population was estimated using incident diagnoses and transition to adult services. Abdominal surgery rates (strictureplasty, resection, primary stoma) and anti-TNF administration were collected and prevalence calculated. Three anti-TNF epochs, defined by the European Crohn's and Colitis Organisation/European Society of Paediatric Gastroenterology, Hepatology and Nutrition guidelines in 2014 and 2020, were compared: Epoch-1 (2007-2013; <20% anti-TNF), Epoch-2 (2014-2020; 20%-50%) and Epoch-3 (2021-2024; >50%). Kaplan-Meier analysis with log-rank testing compared surgery-free survival between early and later anti-TNF treatment groups.
RESULTS: One thousand five hundred and thirty-eight children were included (915 Crohn's disease (CD), 529 ulcerative colitis (UC) and 94 IBD-unclassified). Median age at diagnosis was 13.3 years, and the prevalent population increased (253-597 patients). Anti-TNF-treated prevalence rose across epochs (5.9%, 31.9%, 61.1%; p<0.001). Resection rates declined 3.93%, 1.57% and 1.09% (Epoch 1-3) (p=0.003). Rates did not significantly decrease from Epoch 2 to 3 (p=0.217). CD surgery significantly decreased (4.9%, 1.7%, 1.5%, p=0.006); trends in UC rates did not reach significance (1.89%, 1.55%, 0.56%, p=0.314). Time to anti-TNF from diagnosis decreased (1.2, 0.8 and 0.26 years, p=0.008). Early vs later anti-TNF initiation was not associated with surgery-free survival.
CONCLUSION: We report a significant increase in anti-TNF prevalence, with earlier deployment. Surgical resection rates have declined and plateaued; reflecting reduced CD surgery. Future research should focus on optimised anti-TNF and second-line biologic deployment to move beyond current levels of surgery.
This record has no associated files available for download.
More information
Accepted/In Press date: 15 May 2026
e-pub ahead of print date: 24 June 2026
Identifiers
Local EPrints ID: 512967
URI: https://eprints.soton.ac.uk/id/eprint/512967
ISSN: 2054-4774
PURE UUID: 395d99f4-f15c-45b3-8ca9-525f0bc91e12
Catalogue record
Date deposited: 28 Jul 2026 16:51
Last modified: 13 Sep 2026 15:49
Export record
Altmetrics
Contributors
Author:
Zachary Green
Author:
Myrna Nicholas
Author:
Stephanie Vuijk
Author:
Mike Stanton
Author:
Christopher Bakewell
Author:
Tracy Coelho
Author:
Akshay Batra
Author:
Nadeem Afzal
Author:
Robert M Beattie
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics